MHRA Authorises Lilly's Weekly Insulin Onswik

The UK's Medicines and Healthcare products Regulatory Agency authorised Onswik (insulin efsitora alfa) on 13 October 2026, licensing Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes. The decision clears the one condition NICE's final draft guidance had attached to NHS use two months earlier — and makes the UK the latest of several jurisdictions to license a product that changes a daily injection into a weekly one.

What MHRA licensed

Onswik is dosed once a week rather than once a day, delivered through a pre-filled pen. MHRA's authorisation covers adults with type 2 diabetes, aligning the UK label with the adult-only indications already in place in the US and under EMA's assessment — the QWINT trials enrolled adults aged 18 and over, and Lilly's own prescribing information states that safety and effectiveness in pediatric patients have not been established. For a drug class where the injection itself, not just the drug, is the adherence burden, a licensed weekly basal option is a label change prescribers will notice before any marketing campaign does.

The NICE sequencing

This authorisation does not exist in isolation from the UK's reimbursement process. NICE published final draft guidance on 20 August 2026 recommending Onswik for NHS patients in England and Wales, but the recommendation was explicitly conditional: NICE said at the time that the treatment could not reach NHS or private patients until MHRA granted a licence. That is the sequencing RA/QA teams planning UK launches should track — a positive NICE recommendation is not funding, and a licence is not a formulary listing. With MHRA's decision now in hand, the remaining step is NICE converting its final draft into final guidance, which ordinarily follows a short window for any appeal against the draft recommendation.

A fifth jurisdiction, same drug

Onswik's rollout is a case study in how a single product now clears five separate regulatory processes on five different timelines. The FDA's 24 September 2026 approval described itself as the fourth global approval for Onswik, citing earlier regulatory action in the EU, Japan and Mexico; the specific EU action to that point was a CHMP positive opinion issued 25 June 2026 recommending marketing authorisation, a committee recommendation rather than the European Commission's own decision. The UK's 13 October authorisation — arriving under its own post-Brexit licensing process rather than as a knock-on effect of the EU opinion — is the latest step in that sequence, not a given one. For sponsors, it is a reminder that a US approval date says nothing about when a UK or EU patient can actually access the same product; for RA teams, it is the operational case for tracking each agency's docket independently rather than assuming one approval cascades automatically into the next.

Frequently asked questions

What did the MHRA authorise on 13 October 2026?

A marketing authorisation for Onswik (insulin efsitora alfa), Eli Lilly's once-weekly basal insulin, for adults with type 2 diabetes — a pre-filled pen dosed weekly instead of daily, which MHRA's announcement says can cut injections from up to 365 a year to 52.

Why was NICE waiting on this?

NICE's final draft guidance, published 20 August 2026, recommended Onswik for NHS use in England and Wales but made the recommendation conditional on MHRA granting a UK licence first. The 13 October authorisation clears that condition; NICE's own final guidance follows once any appeal period on the draft closes.

Where else has Onswik been authorised?

The FDA approved Onswik on 24 September 2026, describing it at the time as the fourth global approval for the product, after earlier regulatory action in the EU — a CHMP positive opinion on 25 June 2026 — plus authorisations in Japan and Mexico. The UK's 13 October authorisation follows all of those.

What is the evidence behind it?

The QWINT phase 3 programme, which enrolled more than 3,400 adults with type 2 diabetes across four registration trials. EMA's assessment found once-weekly insulin efsitora alfa lowered HbA1c about as much as once-daily basal insulin comparators, with observed differences ranging from -0.01 to -0.09 percentage points. The most commonly reported side effect is hypoglycaemia.